Bortezomib is a protease inhibitor and is the first compound in this drug class to be used in clinical practice, with trials demonstrating efficacy in patients with relapsed/refractory multiple myeloma. Mature clinical data on the efficacy of bortezomib in solid tumors are not yet available, but early clinical data indicate this could be a promising drug for the treatment of advanced solid tumors. This Review summarizes the principal clinical trials of bortezomib and discusses its efficacy in solid and hematologic tumors.
- Tommaso Caravita
- Paolo de Fabritiis
- Mario Boccadoro
